£8.4M
Vickers Venture Partners led the Series A round to support clinical trials for set-point vaccines.
Emergex
Emergex develops set-point vaccines designed to prevent severe infectious diseases.
£8.4MTotal raised
Emergex is a British biotechnology company developing set-point T-cell vaccines to prevent serious infectious diseases. The firm employs synthetic peptide codes delivered via gold nanoparticle carriers to prime the immune system against viral pathogens.
Categories
Founders
Thomas Rademacher
CEO
Thomas brings founding and leadership experience from Midatech, Emergex, and Oxford Glycosciences, alongside academic roles at University College London and the University of Oxford.